Long QT, Brugada, and CPVT: A Patient's Guide to Inherited Rhythm Disorders That Cause Sudden Death in Hearts That Look Normal

A 17-year-old swimmer collapses at the end of a high school meet. Bystander CPR and a school AED (automated external defibrillator) save her life. In the hospital, her echocardiogram (the ultrasound of the heart) is normal. The cardiac MRI is normal. The coronaries on CT angiography look pristine. By every structural measure, her heart is fine. But her resting EKG shows a QTc of 510 milliseconds (the corrected QT interval, a measure of how long it takes the heart’s electrical system to reset after each beat), and her mother and aunt both have a history of unexplained fainting during exercise. The diagnosis: long QT syndrome, type 1.

That’s the channelopathy story in a sentence. The heart muscle is normal. The plumbing is normal. The problem is microscopic: tiny protein channels in the cell membranes of the heart, the ones that move charged ions in and out to create each heartbeat, are coded by faulty genes. Most of the time the heart works fine. But under specific conditions (a hard sprint, a startling sound, a fever, a particular antibiotic), the electrical system fails and a lethal arrhythmia takes hold. Identifying these conditions before they kill someone is one of the most important things modern cardiology does.

This guide walks through the three most clinically important channelopathies in plain language: long QT syndrome, Brugada syndrome, and CPVT. It covers what each one is, who gets it, how it’s diagnosed, what the treatments are, what family members need, and what daily life looks like with the diagnosis. The patients who do best are the ones who understand what they have and treat it as a long-term partnership with their cardiology team.

What Is a Channelopathy, in Plain English?

A channelopathy is an inherited disorder of the tiny protein channels that move charged particles (ions) in and out of heart cells with each heartbeat. The heart muscle looks normal on every imaging test. The problem is in the microscopic electrical machinery. Under specific triggers, the electrical system can become unstable and cause a dangerous rhythm called ventricular tachycardia or ventricular fibrillation, which can lead to sudden cardiac death.

How a Normal Heartbeat Works at the Cellular Level

Each heart cell has channels in its membrane that allow ions to flow in or out: sodium in, potassium out, calcium in, and so on. The orchestrated flow of these ions creates the action potential, the electrical signal that triggers the cell to contract. Each beat is the result of millions of cells firing in coordinated sequence. The whole process is over in less than a second and repeats 60 to 100 times per minute.

What Goes Wrong in a Channelopathy

The genes that code for these ion channels can carry mutations. The mutated channel may open too slowly, close too slowly, open too easily, or fail to open at all. Depending on which channel is affected and how, the action potential gets distorted: it may last too long, end too abruptly, or destabilize under stress. The heart conducts electricity normally most of the time but becomes vulnerable to dangerous rhythms under specific triggers.

What All Channelopathies Share

A few features run through all the channelopathies covered in this guide:

All are inherited, mostly in autosomal dominant patterns (each child of an affected person has a 50 percent chance of inheriting the gene).

All produce hearts that look structurally normal on echocardiogram, cardiac MRI, and angiography.

All carry a risk of sudden cardiac death from ventricular arrhythmias.

All have specific clinical patterns that, once recognized, allow for diagnosis, treatment, and family screening.

All benefit from being caught before the first cardiac event.

Why Family Screening Matters So Much

Because these conditions are inherited, identifying one affected person in a family often means that other family members are also affected and don’t know it. Cascade screening, where first-degree relatives (parents, siblings, children) are systematically tested, is one of the most important things we do. A patient diagnosed today can lead to three or four family members being identified and protected before they have a first event.

What Is Long QT Syndrome?

Long QT syndrome is the most common inherited channelopathy. The QT interval on the EKG is longer than normal, which means the heart takes too long to electrically reset between beats. When the reset takes too long, the heart becomes vulnerable to a chaotic rhythm called torsades de pointes, which can degenerate into ventricular fibrillation and cause sudden cardiac death. Prevalence is about 1 in 2,000 people.

The Three Main Subtypes

More than 15 genetic subtypes of long QT have been identified, but three account for most cases. Knowing which subtype matters because the triggers and the treatment differ.

LQT1

Caused by mutations in the gene KCNQ1, which codes for a potassium channel called IKs. Arrhythmic events in LQT1 happen almost exclusively during exercise, especially swimming and physical exertion. Swimming is the most distinctive trigger; unexplained near-drowning or drowning in someone who knows how to swim should always raise suspicion for LQT1. Beta-blockers (especially nadolol) are very effective in LQT1, with about 70 to 80 percent reduction in arrhythmic events when patients are on adequate therapy.

LQT2

Caused by mutations in the gene KCNH2 (also called HERG), which codes for a potassium channel called IKr. Patients with LQT2 have events triggered by emotional stress, sudden auditory stimuli (an alarm clock, a phone ringing, a sudden loud noise), and the postpartum period. The auditory trigger is distinctive enough that an alarm clock with a sudden tone in the bedroom is sometimes the precipitating event. Beta-blockers help in LQT2, but the protection is less complete than in LQT1, and many LQT2 patients also need an implantable defibrillator. The hERG channel is also the target of many medications that prolong the QT interval, which means patients with LQT2 are at especially high risk from QT-prolonging drugs.

LQT3

Caused by mutations in the gene SCN5A, which codes for the cardiac sodium channel. Unlike LQT1 and LQT2, LQT3 events tend to occur at rest or during sleep, when the body’s sympathetic nervous system is quiet. Sodium channel blockers (mexiletine in particular) can shorten the QT interval and reduce arrhythmic risk in LQT3, in addition to beta-blockers and an implantable defibrillator for higher-risk patients.

Why the Subtype Matters

A patient with LQT1 needs to be careful about exercise, especially swimming, and benefits from a specific beta-blocker dose schedule. A patient with LQT2 needs to avoid the long list of QT-prolonging medications and should consider removing sudden auditory triggers from the bedroom. A patient with LQT3 needs sodium channel-targeted therapy beyond beta-blockers and may have arrhythmic events during sleep that other long QT patients don’t have. Genetic testing identifies the subtype and shapes the management plan.

How Long QT Is Diagnosed

The starting point is a resting 12-lead EKG with careful measurement of the QT interval, corrected for heart rate. A corrected QT interval (QTc) above 460 milliseconds in adult women or 450 milliseconds in adult men is considered prolonged. A QTc above 480 milliseconds is suggestive of long QT syndrome. A QTc above 500 milliseconds is concerning regardless of clinical context.

The Schwartz score combines EKG findings, clinical history, and family history to estimate the probability of long QT syndrome and is used to guide further workup.

Exercise stress testing is useful because LQT1 patients often show a characteristic prolongation of QT during early recovery from exercise. The QT may also fail to shorten appropriately during peak exercise.

Holter monitoring (a wearable 24 to 48 hour rhythm recorder) can capture arrhythmic events and the QT response to daily activities.

Genetic testing is now standard when long QT is suspected on clinical grounds. A positive genetic test confirms the diagnosis and identifies the subtype. A negative genetic test does not rule out long QT syndrome (only about 70 to 80 percent of clinically diagnosed patients have an identifiable mutation), but when positive, it simplifies family screening.

How Long QT Is Treated

Beta-blockers are the foundation. Nadolol is the most effective and most studied; propranolol is an alternative. Metoprolol and atenolol appear less protective in head-to-head studies. Doses are titrated to control symptoms and ensure adequate beta-blockade during exercise. Compliance matters, since protection wanes within a day or two of stopping the medication.

Lifestyle modification is part of every long QT plan. Avoidance of QT-prolonging medications is critical (see the table below). Avoidance of dehydration and electrolyte abnormalities (low potassium, low magnesium) matters because these can further prolong the QT. Subtype-specific precautions apply: no swimming alone in LQT1, removing sudden alarm-style alerts from the bedroom in LQT2.

An implantable cardioverter-defibrillator (ICD) is recommended for patients who have had a cardiac arrest, who continue to have fainting despite adequate beta-blocker therapy, or who have very high-risk features (very prolonged QTc, certain genetic variants, family history of sudden death).

Left cardiac sympathetic denervation, a surgical procedure that disrupts the sympathetic nerves to the heart on the left side, is an option for patients with refractory disease despite beta-blockers and an ICD. It markedly reduces arrhythmic burden in selected patients.

What Is Brugada Syndrome?

Brugada syndrome is an inherited channelopathy that produces a characteristic EKG pattern (coved ST elevation in the right precordial leads, leads V1 through V3) and carries a risk of ventricular fibrillation, often at rest or during sleep. It’s most common in men of southeast Asian heritage. Mutations in the SCN5A sodium channel account for many cases. Events are often triggered by fever, certain medications, alcohol, or large meals.

Who Gets Brugada

Brugada syndrome was first described in 1992 and is now recognized as an important cause of sudden death, especially in men and especially in those of southeast Asian heritage. The condition is autosomal dominant, but with incomplete penetrance, meaning that even within affected families, some carriers never have events while others do.

The Brugada EKG Pattern

The diagnostic EKG finding is a type 1 Brugada pattern: a coved (downsloping) ST segment elevation of at least 2 millimeters in one or more of the right precordial leads (V1, V2, V3), followed by an inverted T wave. Type 2 and type 3 Brugada patterns (saddle-back morphology) are suggestive but not diagnostic on their own; they often require provocation testing or genetic confirmation.

A normal-looking baseline EKG doesn’t rule out Brugada. The pattern can fluctuate. Provocation testing with a sodium channel blocker (procainamide or ajmaline given intravenously under careful monitoring) unmasks the type 1 pattern in patients with the underlying condition. This test is done in specialized labs with full resuscitation capability.

Triggers in Brugada

Events in Brugada syndrome are often associated with specific triggers:

Fever raises the risk substantially. Patients with Brugada need aggressive treatment of fevers, including acetaminophen at the first sign of elevated temperature.

Certain medications can unmask the pattern or precipitate arrhythmia. The list includes tricyclic antidepressants, some antipsychotics, certain antiarrhythmics (especially class IC drugs like flecainide), and several others. BrugadaDrugs.org maintains a current list that patients should consult before starting any new medication.

Alcohol (especially binge drinking) and large carbohydrate-heavy meals are sometimes associated with events.

Vagal stimulation (the body’s “rest and digest” nerve activity) is associated with events, which is why arrhythmias in Brugada often happen at rest, during sleep, or after meals.

How Brugada Is Diagnosed

A type 1 Brugada pattern on EKG is diagnostic when accompanied by one of the following: documented ventricular fibrillation, polymorphic ventricular tachycardia, family history of sudden death under age 45, type 1 pattern in family members, fainting consistent with arrhythmia, or nocturnal agonal respiration. Without one of these features, the EKG pattern alone (without symptoms) is considered Brugada pattern rather than Brugada syndrome.

Provocation testing with a sodium channel blocker is used when the diagnosis is suspected but the baseline EKG is non-diagnostic. Genetic testing is offered when the diagnosis is established; SCN5A mutations are found in about 15 to 30 percent of patients.

Electrophysiology study (EP study) is sometimes used to assess inducibility of ventricular arrhythmias in selected patients with Brugada to inform the decision about defibrillator implantation. See our guide to EP study and ablation for more on this procedure.

How Brugada Is Treated

The cornerstone of Brugada management is fever control. Patients learn to take acetaminophen at the first sign of fever and to seek medical attention for high or prolonged fevers.

Avoidance of medications and substances on the Brugada drug list. Alcohol moderation. Avoidance of large carbohydrate-heavy meals, especially late at night.

An ICD is recommended for patients who have had cardiac arrest, who have had fainting episodes consistent with ventricular arrhythmia, or who have inducible ventricular arrhythmias on EP study with high-risk features.

Quinidine is the only medication that has been shown to reduce arrhythmic burden in Brugada syndrome. It’s used in patients who have had recurrent appropriate ICD shocks or in selected patients with very high-risk features.

Catheter ablation targeting the right ventricular outflow tract epicardial substrate has emerged as a treatment for patients with refractory ventricular arrhythmias. It’s done at experienced centers and can substantially reduce arrhythmic burden in selected patients.

What Is CPVT?

CPVT stands for catecholaminergic polymorphic ventricular tachycardia. It’s an inherited channelopathy where the heart develops a characteristic rhythm called bidirectional ventricular tachycardia in response to exercise or emotional stress. The hallmark is fainting or near-fainting during exertion in childhood or adolescence, often with a family history of sudden death. Beta-blockers are the cornerstone of treatment.

Who Gets CPVT

CPVT often presents in childhood or adolescence with fainting or cardiac arrest during exertion or strong emotion. The classic presentation is a teenager who collapses while running on a soccer field or during a stressful event. Both autosomal dominant (RYR2 mutations) and autosomal recessive (CASQ2 mutations) inheritance patterns exist. Prevalence is estimated at about 1 in 10,000.

How CPVT Presents

The hallmark is fainting (syncope) during exercise or emotional stress in a child or young adult with a structurally normal heart. The baseline EKG is usually normal at rest. Exercise stress testing reproducibly induces ventricular arrhythmias, often a characteristic pattern called bidirectional ventricular tachycardia, where the QRS axis alternates beat-to-beat.

A family history of sudden death during exercise or stress in a young relative is common. The first cardiac event is sometimes fatal, which is why early recognition and treatment matter so much.

How CPVT Is Diagnosed

The diagnosis is suspected in any young patient with exercise- or stress-induced fainting and a normal baseline cardiac evaluation. The key test is an exercise stress test, which typically reproduces ventricular ectopy progressing to bidirectional or polymorphic ventricular tachycardia as the heart rate climbs. Holter monitoring can capture similar findings during daily activity.

Genetic testing for RYR2 and CASQ2 mutations confirms the diagnosis. As with other channelopathies, a negative genetic test doesn’t rule out CPVT, but a positive test confirms it and enables family screening.

How CPVT Is Treated

Beta-blockers are the foundation. Nadolol is the preferred agent and is dosed to achieve maximal beta-blockade. Doses are higher than for many other indications. Compliance is critical.

Flecainide, a class IC antiarrhythmic, is added to beta-blockers in patients with breakthrough symptoms. Flecainide reduces calcium leak through the abnormal ryanodine receptor and complements beta-blocker therapy.

Left cardiac sympathetic denervation is an option for patients with refractory disease.

An ICD is reserved for patients who have had cardiac arrest. ICDs in CPVT can sometimes cause an electrical storm because shocks themselves trigger more arrhythmia in this condition; the threshold for implantation is therefore higher than in some other channelopathies.

Avoidance of triggering activities is part of every CPVT plan. Most CPVT patients are restricted from competitive sports. Recreational exercise is usually allowed in moderation, especially after beta-blocker treatment is established and exercise stress testing shows acceptable response.

How Are These Conditions Different from a Structurally Abnormal Heart?

The defining feature of channelopathies is a structurally normal heart on imaging. Echocardiogram, cardiac MRI, and coronary imaging all look fine. The problem is microscopic. This contrasts with structural heart diseases like hypertrophic cardiomyopathy (HCM) or arrhythmogenic right ventricular cardiomyopathy (ARVC), where the heart muscle itself is abnormal and the imaging tests show the disease. The treatments and the family screening overlap in important ways, but the workup and the underlying mechanism are different.

Comparing Channelopathies to Structural Conditions

In channelopathies, the heart looks normal but the electrical system is dysfunctional. In conditions like HCM, the heart muscle itself is thickened or otherwise abnormal, and the arrhythmic risk comes from the structural abnormality. Both can present with sudden cardiac death in young people, and both are inherited, but the diagnostic pathway and the treatments differ.

Why This Matters for the Workup

A patient with unexplained cardiac arrest and a normal echo, normal MRI, and normal coronaries needs evaluation for channelopathies. A patient with a thick heart on echo or an enlarged right ventricle on MRI needs a structural workup. Sometimes both pathways apply (a patient can have both a structural condition and a separate inherited rhythm disorder), but the initial split is between structural and channelopathic.

How Should I Prepare for a Channelopathy Evaluation?

Bring a careful personal history: every fainting episode, every near-faint, every weird “almost passed out” moment, what you were doing, how quickly you recovered. Bring a careful family history: anyone who died young or unexpectedly, anyone who had unexplained car accidents or drownings, anyone with a pacemaker or defibrillator. Bring a complete medication list including over-the-counter drugs. Be ready for an EKG, an exercise stress test, an echocardiogram, and possibly an extended Holter or patch monitor.

Personal History to Document

Every fainting episode: what you were doing, what you felt before, how long unconscious, how you felt after.

Every near-faint or “I almost passed out” moment, even if brief.

Episodes of palpitations, especially with lightheadedness.

Symptoms during exercise: any unusual chest discomfort, lightheadedness, near-faint, or actual fainting.

Symptoms with sudden noises or emotional triggers.

Any episodes during sleep that someone noticed (gasping, agonal breathing, witnessed seizure-like activity).

Family History to Gather

Anyone who died suddenly, especially under age 50.

Anyone who died in an unexplained car accident or unexplained drowning.

Anyone with unexplained fainting episodes.

Anyone with a pacemaker, defibrillator, or arrhythmia diagnosis.

Anyone known to have long QT, Brugada, CPVT, hypertrophic cardiomyopathy, or another inherited heart condition.

Anyone with seizure disorders or unexplained convulsions (some “seizures” in family members turn out to have been arrhythmic events).

Medication and Substance Use

Bring a complete medication list including over-the-counter drugs (especially decongestants, sleep aids, allergy pills), supplements, and herbal preparations.

Mention alcohol use, recreational drug use (especially stimulants, cocaine, MDMA), and energy drink consumption.

Mention any specific medication that seems to have triggered symptoms.

What to Expect at the First Visit

A careful history. A focused exam. A baseline EKG with careful QT measurement and assessment for any Brugada pattern. Often an echocardiogram to rule out structural heart disease. Often an exercise stress test, especially for suspected LQT or CPVT. Often a 24 to 48 hour Holter monitor or a 14-day patch monitor.

Genetic counseling and possibly genetic testing if a channelopathy is confirmed or strongly suspected.

Discussion of family screening: which relatives should be evaluated, how, and when.

What Does Daily Life Look Like With a Channelopathy?

It depends on the diagnosis, the subtype, the risk stratification, and the treatments in place. Most patients can live close to normal lives with appropriate precautions: adherence to beta-blockers, avoidance of specific triggers, fever management for Brugada, avoidance of QT-prolonging drugs for long QT, modified or restricted exercise for some patients with CPVT or high-risk LQT. The patients who do worst are the ones who stop their beta-blocker or who ignore the trigger guidance.

Beta-Blocker Compliance

For all three channelopathies, beta-blockers are central to risk reduction. Nadolol is preferred in long QT and CPVT. The medication must be taken every day. Missing doses substantially reduces protection. Use a daily reminder, a pillbox, or a smartphone app to maintain consistency.

Trigger Avoidance

LQT1: avoid swimming alone. Always swim with a partner who knows the diagnosis. Avoid competitive swimming unless explicitly cleared by your electrophysiologist.

LQT2: remove sudden auditory alarms from the bedroom. Use gradual-wake alarms or vibrating alarms. Avoid phone ringtones with sudden onset.

LQT3: events can happen during sleep. Bedside ICDs (in patients with one) need to be on. Sleep partners should know the diagnosis and what to do in the event of an unwitnessed unresponsive event.

Brugada: aggressive fever management. Acetaminophen at the first sign of fever. Seek care for fevers above 102 or fevers lasting more than 24 hours. Avoid all drugs on BrugadaDrugs.org.

CPVT: usually no competitive sports. Recreational exercise allowed in moderation, often guided by exercise stress test response on beta-blocker.

Medication Card and Medical Alert

Carry a medication card or a medical alert bracelet that lists your diagnosis (long QT subtype, Brugada syndrome, CPVT), your medications (especially nadolol), and a contact number for your cardiologist. Show it to any healthcare provider who’s prescribing for you or treating you in an emergency.

Drug Lists to Know

For long QT: CredibleMeds.org maintains a current list of drugs that prolong the QT interval. Check the list before starting any new medication, including over-the-counter drugs.

For Brugada: BrugadaDrugs.org maintains a current list of drugs to avoid. Check the list before any new prescription.

For CPVT: stimulants (including some ADHD medications), cocaine, and other catecholamine-releasing substances should be avoided.

Exercise Guidance

The exercise restrictions depend on the diagnosis and subtype.

LQT1: most patients are restricted from competitive swimming. Other exercise allowed in moderation while on beta-blockers, with annual exercise stress test reassessment.

LQT2 and LQT3: exercise generally allowed in moderation with beta-blockers.

Brugada: exercise generally allowed.

CPVT: usually no competitive sports. Recreational exercise allowed in moderation with beta-blockers; guidance is individualized.

Pregnancy and Delivery

Pregnancy and the postpartum period are higher-risk windows for women with channelopathies, especially LQT2 (where the postpartum period is associated with events). Continued beta-blocker therapy through pregnancy is usually advised. Delivery in a hospital with cardiac monitoring and access to a defibrillator is recommended.

Travel

Travel is fine for most patients. Bring enough medication for the entire trip plus extra. Carry your medication card and medical alert. Know how to access emergency care at your destination. Avoid extreme heat or dehydration.

Driving

Driving restrictions vary based on the diagnosis and whether there’s been a cardiac event. After a cardiac arrest or fainting episode, driving is typically restricted for 6 months and longer for commercial driving. After an ICD shock, restrictions apply per state law. Discuss specific guidance with your cardiologist.

What Do Family Members Need?

Every first-degree relative (parent, sibling, child) of a person diagnosed with a channelopathy should be screened. The screening starts with a careful family-history evaluation, an EKG, and often genetic testing if a specific mutation is known in the family. Cascade screening identifies affected relatives before they have their first event, which is the most effective intervention we have for these conditions.

Who Gets Screened

First-degree relatives first: parents, siblings, biologic children.

If first-degree relatives are positive, their first-degree relatives are screened next (extending outward through the family tree).

In families with established mutations, genetic testing of relatives is the most accurate way to identify carriers.

What the Screening Visit Looks Like

A family history review. A baseline EKG with QT measurement and Brugada pattern assessment. An echocardiogram if there’s any concern for structural disease. Genetic testing if the index patient has an identified mutation. Sometimes an exercise stress test or Holter monitor.

What Happens If a Relative Is Positive

The relative starts on the appropriate management plan, often beta-blocker therapy and lifestyle precautions. They consider whether they need an ICD based on their risk profile. They proceed to screening of their own first-degree relatives.

What Happens If a Relative Is Negative

If a specific mutation is known in the family and the relative tests negative for that mutation, they can usually be reassured that they are not at risk and their children also won’t be at risk from that mutation. If only clinical screening was done (no specific mutation identified), the reassurance is somewhat less definitive, but a normal baseline workup substantially lowers the suspected risk.

Why Cascade Screening Saves Lives

Channelopathies are highly inheritable. A single proband (the first person identified in a family) often leads to identification of three or four affected relatives. Each of those relatives, once identified and started on treatment, has dramatically lowered risk of sudden death. Cascade screening is one of the highest-value interventions in modern cardiology.

When Should I Call Emergency Services?

Call 911 for any cardiac arrest, any prolonged or recurrent fainting, any new chest pain with lightheadedness, any fever above 102 in a Brugada patient, any sustained palpitations with lightheadedness, or any ICD shock (whether one or many). Don’t wait to see if symptoms resolve; these conditions can produce events that are sudden and catastrophic.

Immediate ER Trip For:

Witnessed cardiac arrest. Prolonged loss of consciousness or recurrent fainting episodes. New chest pain with lightheadedness or fainting. Sustained palpitations with lightheadedness or fainting. Fever above 102 in a Brugada patient. Any ICD shock (whether the patient feels well or not). Witnessed gasping or agonal breathing.

Same-Day Office Call For:

New or worsening symptoms despite the current treatment plan. Missed beta-blocker doses with breakthrough symptoms. A new medication that may interact (call before taking the next dose if possible). Any new fainting or near-fainting episode.

Routine Visit For:

Annual or semi-annual follow-up. Genetic counseling questions. Family planning discussions. Activity clearance for new exercise or sports.

Common Questions Patients Ask Me

What does it mean if my QT interval is borderline?

A borderline QT interval (470 to 490 milliseconds) is suggestive but not diagnostic. The next steps include repeat EKGs, exercise stress testing, Holter monitoring, careful symptom and family history, and sometimes genetic testing. About 10 to 15 percent of healthy people have borderline QTs without long QT syndrome. The Schwartz score helps integrate the findings to estimate probability.

Can I exercise if I have long QT syndrome?

For most patients with LQT2 and LQT3, exercise is allowed in moderation while on beta-blockers, with annual reassessment by exercise stress testing. For LQT1 patients, swimming alone is restricted, and competitive swimming is usually off the table. The specific guidance is individualized.

What if I get a fever with Brugada syndrome?

Take acetaminophen at the first sign of elevated temperature. Maintain hydration. Seek medical care for fevers above 102 or fevers lasting more than 24 hours, or for fevers with any new symptoms (chest pain, palpitations, fainting).

My child has CPVT. Can they play sports?

Most CPVT patients are restricted from competitive sports. Recreational exercise is usually allowed in moderation, especially after beta-blocker treatment is well-established and an exercise stress test shows acceptable response. The decision is individualized and made with a pediatric electrophysiologist.

Should everyone in my family be tested?

First-degree relatives (parents, siblings, children) should all be screened. If they’re positive, their first-degree relatives are next. Cascade screening is one of the most valuable interventions we have for these conditions.

Is a defibrillator always necessary?

No. ICDs are reserved for patients with the highest risk: those who have had cardiac arrest, those with recurrent fainting despite optimal medical therapy, and selected high-risk patients based on specific genetic and clinical features. Most channelopathy patients are managed with medications and lifestyle alone.

What medications should I never take?

For long QT: avoid everything on the CredibleMeds.org “known risk” list, including some antibiotics (azithromycin, levofloxacin, moxifloxacin), antifungals (fluconazole), antipsychotics (haloperidol, ziprasidone), antidepressants (citalopram at higher doses), antiemetics (ondansetron), and others.

For Brugada: avoid everything on the BrugadaDrugs.org list, including tricyclic antidepressants, some antipsychotics, and class IC antiarrhythmics (flecainide).

For CPVT: avoid stimulants, including some ADHD medications, cocaine, and other catecholamine-releasing substances.

Can I have surgery safely?

Yes, with planning. Tell the anesthesiologist about your condition. Some anesthetic drugs prolong the QT and should be avoided or monitored. Continue beta-blockers through the perioperative period. For Brugada patients, fever during surgery or recovery needs immediate aggressive treatment.

Will I pass this to my children?

For autosomal dominant conditions (most long QT, Brugada, and CPVT), each child has a 50 percent chance of inheriting the gene. Genetic counseling can help you understand the inheritance pattern in your specific case and consider options like preimplantation genetic diagnosis if you’re planning a pregnancy.

How often do I need to be seen?

Most stable channelopathy patients are seen every 6 to 12 months. Patients with recent diagnoses, recent events, or medication changes are seen more often. Annual or semi-annual EKGs and periodic Holter monitoring or exercise stress testing are common. ICD patients have device interrogations on a regular schedule.

Are there new treatments coming?

Yes. Gene therapy approaches are in early clinical development for some channelopathies. New medications targeting specific ion channel abnormalities are in trials. Improved risk stratification using genetic and clinical features is steadily refining who needs an ICD and who can be managed with medications alone.

What if I have lightheadedness episodes? Could they be related?

Possibly. Any new fainting or near-fainting episode in a channelopathy patient warrants evaluation. Sometimes it’s an arrhythmic event that the device detected; sometimes it’s a vasovagal or orthostatic episode unrelated to the channelopathy. Our guide to lightheadedness vs passing out covers how the workup branches.

Reference Tables

Comparison of the Three Channelopathies

Common QT-Prolonging Medications to Know About (Not Complete; Check CredibleMeds.org)

What Family Members Need

A Final Note From Me

The channelopathies are diagnosable, treatable, and largely manageable when caught early. The catch is recognizing them. The patient with unexplained fainting during exercise. The young athlete with a family history of sudden death. The teenager who collapses during emotional stress. The middle-aged man with a fainting episode after a fever. The EKG that shows a Brugada pattern or a long QT. Each of these is a moment when the right next step matters enormously.

The patients who do best are the ones who understand their condition, take their beta-blocker every day, follow the trigger-avoidance guidance, carry their medication list, and bring their first-degree relatives in for screening. The patients who do worst are the ones who stop their beta-blocker because they feel fine, who skip the medication review before a new prescription, or who don’t tell the anesthesiologist about the diagnosis before surgery.

Family screening is the single most consequential intervention we make for these patients. A single proband often leads to three or four newly identified relatives, each of whom can be protected before their first event. If you’ve been diagnosed, please bring your first-degree relatives in. Their lives often depend on it.

If you have questions about a known channelopathy diagnosis, suspect you might have one based on symptoms or family history, or have a family member who was recently diagnosed and you need screening, our office can help. To get in touch, visit our practice website. For specialized inherited arrhythmia evaluation and genetic counseling, we work with the electrophysiology and genetics teams at San Diego Cardiovascular Associates.

References

1. Schwartz, Peter J., Lia Crotti, and Roberto Insolia. “Long-QT Syndrome: From Genetics to Management.” Circulation: Arrhythmia and Electrophysiology 5, no. 4 (2012): 868-877.

2. Priori, Silvia G., Carina Blomstrom-Lundqvist, Andrea Mazzanti, et al. “2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.” European Heart Journal 36, no. 41 (2015): 2793-2867.

3. Brugada, Josep, Begona Benito, Ramon Brugada, et al. “Brugada Syndrome: Diagnosis and Management.” European Heart Journal 39, no. 16 (2018): 1456-1466.

4. Priori, Silvia G., Carlo Napolitano, Mirella Memmi, et al. “Clinical and Molecular Characterization of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia.” Circulation 106, no. 1 (2002): 69-74.

5. Ackerman, Michael J., Silvia G. Priori, Stephan Willems, et al. “HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies.” Heart Rhythm 8, no. 8 (2011): 1308-1339.

6. Wilde, Arthur A. M., and Hugues Abriel. “Cardiac Sodium Channel Mutations: Why So Many Phenotypes?” Nature Reviews Cardiology 8, no. 6 (2011): 339-348.

7. Towbin, Jeffrey A. “Inherited Cardiomyopathies and Channelopathies.” Journal of the American College of Cardiology 64, no. 23 (2014): 2546-2563.

8. Ackerman, Michael J., Bryan C. Cannon, Christopher Carlson, et al. “Care of the Athlete with Genetic Cardiovascular Conditions.” Journal of the American College of Cardiology 66, no. 21 (2015): 2424-2438.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.